Sarcomas are rare malignant tumors derived from connective tissue. Although a substantial group of sarcomas are characterized by a defined chromosomal translocations, the molecular basis for most subtypes of sarcomas are unknown. In collaboration with investigators at MGH, DFCI, and The Broad Institute, we utilize high-throughput genotyping technology to understand the molecular basis of sarcomas in order to gain insight into novel therapeutic options for patients who otherwise have no treatment alternatives.
In addition to this translational approach, our clinical research team collaborates closely with the sarcoma team at DFCI in testing novel agents in our patient population in a phase I, II, or III setting. We are currently enrolling patients onto clinical trials perturbing the VEGF, PDGFR, PARP, IGF1R, mTor, src, DR5, VEGF, c-met, and hsp-90 pathways.